BioMarin Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioMarin Pharmaceutical (BMRN).

Price Target Range — 10 Quarters

Analyst Consensus — 28 Analysts

20Buy

8Hold

Consensus RatingBuy# Analysts28Avg. Consensus PT$89Upside to Avg. PT+58.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$124→$122
Oct 20, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$86→$87
Oct 20, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Maintained	Overweight	$86
Oct 15, 2026	UBS	Joon Lee	Assumes	Buy	$114→$88
Oct 14, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$111→$114
Sep 10, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	$60
Sep 1, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$88→$90
Aug 31, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$104→$105
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Neutral	$59→$60
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$98
Aug 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Neutral	$60→$59
Aug 17, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$82→$88
Aug 17, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$105→$111
Aug 10, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$111→$114
Aug 7, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$119→$124
Aug 7, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$95→$97
Aug 7, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Neutral	$50→$60
Jul 16, 2026	Citigroup	Eric Joseph	PT Raise	Buy	$75→$76
Jul 7, 2026	RBC Capital	Luca Issi	PT Cut	Sector Perform	$66→$62
May 22, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$116→$111

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $88 to $90.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.

Benzinga Newsdesk

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

PRO
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

PRO
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

PRO
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

People Also Watch

People Also Watch

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

PROCantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

PROBarclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

PROHC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PROPiper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

PROJefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

PRO
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

PRO
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

PRO
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105